May 8, 2025, 00:36

Curebound Cure Prizes 2025: $1M Collaborative Cancer Research Challenge

Curebound invites Letters of Intent for its Cure Prizes 2025, a high-impact funding opportunity that awards up to $1,000,000 over 2–3 years for groundbreaking, collaborative, and translational cancer research with near-term clinical application. Projects must aim to significantly improve outcomes for typically fatal cancers, with an expected impact within 3–5 years.

Who is eligible?

Principal Investigators (Team Leads) must:

Hold an MD, PhD, or equivalent
Be independent researchers based at one of the following San Diego institutions:
- UC San Diego (including Moores Cancer Center and UCSD Health)
- Salk Institute
- Sanford Burnham Prebys
- Rady Children’s Hospital
- La Jolla Institute for Immunology
- Scripps Research
Include at least one Partner PI from a different eligible institution
Collaborations beyond San Diego may be approved upon request

Funding at a glance:

Up to 1,000,000 USD over 2–3 years
Max 500,000 USD in Year 1
Indirect costs capped at 30% of total budget
Allowable: PI salaries (within NIH cap), research personnel, supplies, and reagents
Not allowable: Travel, tuition, unrelated infrastructure, or indirects above 30%

Research focus:

Proposals must align with one or more of Curebound’s 5 strategic research pillars:

Prevention + Diagnostic Tools
Cancer Equities
Novel Therapeutics + Platforms
Immunotherapies + Personalized Vaccines
Pediatric Cancers

Emphasis is placed on innovations in therapeutics, diagnostics, immunotherapy, biomarkers, genomics, and underserved populations. Proposals must be interdisciplinary and show potential for clinical translation, including trials, regulatory filings, or novel clinical applications.

Key deadlines:

Letter of Intent Due: May 5, 2025 (5 PM PDT)
Invitation to Apply: June 17, 2025
Full Proposal Deadline: July 29, 2025 (5 PM PDT)
Award Notification: December 2025
Potential Start Date: January 1, 2026

Where to apply:

Submit through ProposalCentral. Full instructions and templates are available on the portal.

Contact:

Program inquiries: [email protected]
Tech support: [email protected] or 1-800-875-2562

Curebound encourages participation in its community events and requires all awardees to engage in program follow-up, peer review, and collaborative reporting. This opportunity offers not just funding, but a platform for impact across research, clinical, and community domains.

cancer equities cancer innovation Cancer research clinical application Cure Prizes Curebound Diagnostics immunotherapy interdisciplinary research OncoDaily Pediatric cancer proposalCENTRAL Research Grants San Diego biotech Translational Oncology

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection